% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Poschke:130347,
      author       = {I. Poschke$^*$ and M. Flossdorf$^*$ and R. Offringa$^*$},
      title        = {{N}ext-generation {TCR} sequencing - a tool to understand
                      {T}-cell infiltration in human cancers.},
      journal      = {The journal of pathology},
      volume       = {240},
      number       = {4},
      issn         = {0022-3417},
      address      = {Bognor Regis [u.a.]},
      publisher    = {Wiley},
      reportid     = {DKFZ-2017-05426},
      pages        = {384 - 386},
      year         = {2016},
      abstract     = {Tumour-infiltrating lymphocytes (TILs) are known to mediate
                      potent anti-tumour activity. As T-cell-based therapies start
                      to reach clinical practice, it becomes increasingly
                      important to understand what characterizes a successful
                      anti-tumour T-cell response and to exploit this knowledge
                      for patient stratification. Next-generation sequencing of
                      T-cell receptors (TCRs) promises to provide insights into
                      the complexity of the tumour T-cell infiltrate that go
                      beyond the phenotypic level. A recent study by Chen et al
                      made use of this novel technology to demonstrate that the
                      TIL repertoire of oesophageal squamous cell carcinoma
                      patients is distinct from that of non-tumour sites and is
                      characterized by significant intratumoural heterogeneity.
                      This study illustrates the great potential of the method and
                      addresses several technical and biological hurdles that need
                      to be considered. Careful sampling, normalization, and error
                      correction will be required to optimally use TCR sequencing
                      to answer biological questions and define predictive
                      biomarkers, e.g. for cancer immunotherapy. Copyright © 2016
                      Pathological Society of Great Britain and Ireland. Published
                      by John Wiley $\&$ Sons, Ltd.},
      cin          = {G180},
      ddc          = {610},
      cid          = {I:(DE-He78)G180-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27569598},
      doi          = {10.1002/path.4800},
      url          = {https://inrepo02.dkfz.de/record/130347},
}